Article
Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.
Antimicrobial agents and chemotherapy - 1 Jul 2015
Song Zehua, Clain Jérôme, Iorga Bogdan I, Yi Zhou, Fisher Nicholas, Meunier Brigitte
Abstract excerpt
The bc1 complex is central to mitochondrial bioenergetics and the target of the antimalarial drug atovaquone that binds in the quinol oxidation (Qo) site of the complex. Structural analysis has shown that the Qo site residue Y279 (Y268 in Plasmodium falciparum) is key for atovaquone binding. Consequently, atovaquone resistance can be acquired by mutation of that residue. In addition to the probability of amino...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.